Surrozen, Inc. (SRZN): Capital Expenditures
$128.0K
Year ended 2025-12-31
$222.0K
Trailing 12 months to 2026-06-30
-44.0%
3-year compound annual growth
-31.9%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $128.0K | +392.3% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $26.0K | -93.5% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $398.0K | -45.3% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $728.0K | -42.6% | 2024-04-10, From 2022-01-01 |
| 2021-12-31 | $1.27M | +45.2% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $874.0K | n/a | 2022-03-28, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Surrozen, Inc. (SRZN) | 2025-12-31 | $128.0K | +392.3% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $914.0K | -51.9% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $134.0K | -42.7% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $185.0K | -94.5% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $4.53M | -37.9% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $23.0K | n/a |
| Aligos Therapeutics, Inc. (ALGS) | 2024-12-31 | $130.0K | +584.2% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $532.0K | -77.2% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $884.0K | -43.8% |
Compare SRZN, CRSP, CGON, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗